Related Experiment Video
Updated: Jul 9, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
What does serum fibroblast growth factor 23 do in hemodialysis patients?
1Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA. m.emmett@baylorhealth.edu
Abstract:
Fibroblast growth factor 23 (FGF-23) is a phosphate-regulating substance largely produced by osteocytes. Its major action, in normal subjects, is the inhibition of Na-coupled reabsorption of inorganic phosphate in the renal proximal tubule. FGF-23 levels increase markedly in dialysis patients. Why do the FGF-23 levels increase in these patients, and do they have any physiologic or pathophysiologic effects?
Related Concept Videos
Serum Studies: Renal Function Tests
Hemodialysis III: Nursing Management
Hemodialysis I: Introduction
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Hemodialysis II: Procedure and Complications
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration